USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
01 Jun 2021 | 02:30 PM GMT

The Power of DTx-generated Real-World Data

Anchored by:

Connor Curtin
Philip Russmeyer
CEO
FITFILE

Participants:

Connor Curtin
Connor Curtin
Philip Russmeyer CEOFITFILE
Philip Russmeyer
CEOFITFILE
Aahuti Rai NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Aahuti Rai
NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
George Platings Director of Business DevelopmentuMotif
George Platings
Director of Business DevelopmentuMotif
Jin Lee Director of Digital HealthAstellas Pharma, Inc
Jin Lee
Director of Digital HealthAstellas Pharma, Inc
Kasparas Aleknavicius Medical AdvisorKilo.Health
Kasparas Aleknavicius
Medical AdvisorKilo.Health
Thomas Leja Senior Director, Digital DiagnosticsAstraZeneca
Thomas Leja
Senior Director, Digital DiagnosticsAstraZeneca

About this Meeting

The FDA has rightly pointed out the following use cases for Real-World Data (RWD) & Real-World Evidence (RWE): 

  •  FDA uses RWD and RWE to monitor postmarket safety and adverse events and to make regulatory decisions. 
  •  The health care community is using these data to support coverage decisions and to develop guidelines and decision support tools for use in clinical practice
  •  Medical product developers are using RWD and RWE to support clinical trial designs (e.g., large simple trials, pragmatic clinical trials) and observational studies to generate innovative, new treatment approaches. 
 With this in mind, how can pharma companies use RWD to improve their commercial and marketing strategies? Are DTx companies leveraging these valuable benefits to close deals with pharma? Join this informal conversation to discuss the power of DTx-generated RWD with other thought leaders in the industry.